Human papillomavirus (HPV) infection is common and causes a wide spectrum of disease.
With recent advances in the development of prophylactic HPV vaccines, it is likely that these …

Human papillomavirus (HPV) is responsible for 99.7% of cervical cancer. Worldwide,
cervical cancer causes more deaths than any other cancer, around one every two minutes …

Since the introduction of the HPV vaccine, questions have been asked about its efficacy in
preventing cancer linked with HPV. Concerns about the HPV vaccine safety profile have …

Human papillomavirus (HPV) is a significant source of morbidity and mortality throughout the
world and is the most common sexually transmitted infection in the United States. HPV is the …

Vaccination against human papillomavirus (HPV) promises to dramatically decrease the
incidence of HPV-related diseases, including cervical cancer. Although this vaccine is …

Approximately 250,000 women die every year of cervical cancers caused by human
papillomavirus (HPV). Most of these could have been prevented by the currently available …

Human papillomavirus (HPV) infections cause several common gynecologic problems.
Oncogenic HPV infections are responsible for abnormal cervical cytology, cervical …

Clinical trials for prophylactic human papillomavirus (HPV) vaccines have shown
overwhelmingly positive results. It is expected that with good coverage of the vaccine, 70 …

Prophylactic HPV vaccines have demonstrated high efficacy against a range of HPV related
diseases. They have been widely adopted as population health interventions in many …

Vaccines against HPV infections have the potential to be a more practical and cost–effective
way to reduce the incidence of cervical cancer. Two candidate HPV vaccines, both …